Frankfurt The share price of the French-Austrian biotech company Valneva rose by double digits on Thursday. By late Thursday afternoon, after the resumption of trading, which had been suspended in the meantime, it was 20 percent above the start of the day at over 20 euros.

The trigger for this is that the British Medicines Agency approved the Covid 19 vaccine developed by Valnea. Britain is the first country in Europe to approve the vaccine. According to this, adults between the ages of 18 and 50 can receive the inactivated vaccine against the corona virus in the future.

The vaccine is based on a process that is widely used in the manufacture of influenza and polio vaccines and is easier to store than mRNA vaccines. Valneva hopes that the European Medicines Agency (EMA) will also grant approval in April. The EU has already ordered 60 million doses of the vaccine, dubbed VLA2001.